Localized amyloidosis at the site of repeated insulin injection in a diabetic patient

Internal Medicine

Volumn 49, Issue 5, 2010, Pages 397-401

  Shikama, Yasuyoshi ^a,b   Kitazawa, Jun Ichi ^b   Yagihashi, Nobuo ^b   Uehara, Osamu ^b   Murata, Yuuji ^b   Yajima, Nobuhisa ^a   Wada, Ryuichi ^a   Yagihashi, Soroku ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Kuroishi City Hospital   (Japan)

Author keywords

Insulin injection; Insulin resistance; Localized amyloidosis

Indexed keywords

AMYLIN; AMYLOID; C REACTIVE PROTEIN; CONGO RED; HEMOGLOBIN A1C; INSULIN ANTIBODY; NITROGEN; PERMANGANATE POTASSIUM; RECOMBINANT HUMAN INSULIN; UREA;

ADULT; AMYLOIDOSIS; ANAMNESIS; ARTICLE; BODY MASS; CASE REPORT; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LABORATORY TEST; MICROSCOPY; TREATMENT DURATION;

ABDOMEN; AMYLOID; AMYLOIDOSIS; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED;

EID: 77749333254     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2633     Document Type: Article

References (9)

1. Westermark P, Araki S, Benson MD, et al. Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, Part 1. Amyloid 6: 63-66, 1999.
2. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature. Amyloid 9: 197-200, 2002.
3. Uversky VN, Fink AL. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 1698: 131-153, 2004.
4. Dische FE, Wernstedt C, Westermark GT, et al. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 31: 158-161, 1988.
5. Swift B. Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med 19: 881-882, 2002.
6. Albert SG, Obadiah J, Parseghian SA, et al. Severe insulin resistance associated with subcutaneous amyloid deposition. Diabetes Res Clin Pract 75: 374-376, 2007.
7. Morten IJ, Gosal WS, Radford SE, Hewitt EW. Investigation into the role of macrophages in the formation and degradation of beta 2-microglobulin amyloid fibrils. J Biol Chem 282: 29691-29700, 2007.
8. Zaghi J, Goldenson B, Inayathullah M, et al. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 117: 111-124, 2009.
9. Bennett RG, Hamel FG, Duckworth WC. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amyloid-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 52: 2315-2320, 2003.